|
new review article cites statistics on efficacy of different targeted drug combos for
Stage IVs:
The Breast
Volume 22, Issue 1 , Pages 1-12, February 2013
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte L. Nielsen, Iben Kümler, Jesper A.E. Palshof, Michael Andersson
Received 15 May 2012; received in revised form 10 July 2012; accepted 23 September 2012. published online 18 October 2012.
Abstract
Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in metastatic breast cancer (MBC).
We review the efficacy of HER2-directed therapies, focussing on monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 that have been tested in phase II–III studies in MBC.
Trastuzumab is an important component of first-line treatment of HER2-positive MBC. New anti-HER2 drugs have the potential to change clinical practice. The potential role of the different drugs and regimens is yet to be determined. The response rate for trastuzumab-DM1 of 26–64% is comparable to those obtained for capecitabine plus lapatinib (48%), continuing trastuzumab in combination with capecitabine (48%), pertuzumab plus trastuzumab (24%), and neratinib (24%). Strategies combining multiple HER2-directed therapies might yield additive or synergistic effects and lead to improved outcome.
The future challenges include understanding HER2 functions, designing rational combinations and optimal selection of patients.
|
Linear Mode
